First patient enrolled into Phase III moxetumomab study, AstraZeneca accelerates cancer drug testing

Standard

Cheers to Astrazeneca

New Drug Approvals

LONDON, May 16 2013

 AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukaemia as the group’s new CEO delivers on a promise to accelerate its oncology programmes.

Britain’s second-biggest drugmaker said on Thursday the Phase III clinical trial would test moxetumomab pasudotox in patients with hairy cell leukaemia who have not responded to or have relapsed after standard therapy.

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s